Shield Therapeutics plc (LON:STX – Get Free Report) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 3.70 and last traded at GBX 3.80, with a volume of 1146595 shares. The stock had previously closed at GBX 3.85.
Shield Therapeutics Stock Down 1.3%
The business’s fifty day moving average price is GBX 5.84 and its 200 day moving average price is GBX 7.73. The firm has a market capitalization of £40.64 million, a price-to-earnings ratio of -1.90 and a beta of 1.76. The company has a current ratio of 0.90, a quick ratio of 2.16 and a debt-to-equity ratio of -199.87.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
